The genitourinary drugs are anticipated to grow at a low CAGR during the forecast period. The genitourinary drugs market is anticipated to witness a considerable growth rate due to the rising prevalence of genitourinary diseases and growing awareness regarding it. As per the Centers for Diseases Control and Prevention (CDC), urinary tract infections are a common infection demanding medical care and causing around 9.6 million ambulatory care visits. The economic burden of urinary tract infection is around $ 2 million per year. However, the growing advent of counterfeit drugs and lack of compliance to medication are the factors that are hampering the growth of the genitourinary drugs market.The factor such as growing healthcare expenditure, increasing per capita income and rising aging population has witnessed a positive impact on the growth of the genitourinary drugs market in emerging economies. The improvement of the healthcare infrastructure that includes a robust increase in the number of clinics and hospitals is expected to boost the growth of the market.

The genitourinary disorders are the conditions in the urinary tract and genital organs. The condition in these parts of the human body may occur owing to several bacterial infections. These drugs are used for the treatment of various diseases includes erectile dysfunction, urinary tract infections, urinary incontinence, glomerulonephritis, chronic renal failure, and genitourinary cancers. Lifestyle disorders that include strokes and autoimmune conditions such as obesity, multiple sclerosis, and diabetes or age-related ailments including Alzheimer's are considered responsible for genitourinary conditions. The prevalence of health conditions is growing across the globe owing to a sedentary lifestyle. Such a large prevalence of genitourinary disorders propels the growth of the market over the forecast period. 

Segmental Outlook  

The global genitourinary drugs market is segmented on the basis of product and disease. Based on product, the market is segmented hormonal therapy, impotence agents, uterine relaxants, urinary antispasmodics, urinary pH modifiers, uterine stimulants, and miscellaneous genitourinary tract agents. The genitourinary drugs market is expected to grow significantly owing to the presence of extensive drug pipelines which is offering a larger product range for reproductive disorders among men and women. Moreover, a large focus of government healthcare organizations on the improvement of reproductive health is expected to offer lucrative growth opportunities. Based on disease, the market is segmented into erectile dysfunction, urinary tract infections, urinary incontinence, glomerulonephritis, chronic renal failure, genitourinary cancers, and others such as STD.

Genitourinary cancers to hold significant market share

Genitourinary cancer includes various types of cancers such as adrenal cancer, bladder cancer, kidney cancer, penile cancer, prostate cancer, and testicular cancer. Among these, prostate cancer is growing significantly across the globe. The market for genitourinary canceris expected to hold a significant market share in the genitourinary drugs market. Owing to a large range of therapeutics includes immunotherapy medications, antineoplastic agents and radio pharmaceuticals for the treatment of these types of cancer. The advantages include impeded disease progression, limited adverse effects;heightened survival chances are growing their uptake into the genitourinary drugs market. 

Regional Outlook

The global genitourinary drugs market is further segmented based on geography including North America, Europe, Asia-Pacific and Rest of the World. North America is expected to hold a considerable market sharein the genitourinary drugs market during the forecast period due to increasing healthcare infrastructure, technological advancements in the manufacturing of genitourinary drugs and awareness regarding the increasing prevalence of cancer. Moreover, the market growth is attributed to the large prevalence of genitourinary disorders in the region. For instance, prostate cancer that has a larger share of all cancer types is the second most leading cause of cancer-related mortality that has a considerable factor contributing to the high demand for therapeutics in the region. 

Global Genitourinary Drugs Market Growth, by Region 2019-2025

Asia-Pacific will augment with the fastest rate in the genitourinary drugs market

The market in the Asia-Pacific region is expected to be the fastest-growing region mainly owing to high R&D investments offered by the major players and their efforts to commercialize therapeutics at a relatively less price. Moreover, the high incidence rate of target disorders, continuous enhancement in healthcare infrastructure and growing disposable income that increases the probability of utilization of branded drugs have a considerable growth opportunity during the forecast period. Additionally, growth is owing to the robust R&D intensity and the rising awareness in developing economies such as India and China.  

Market Players Outlook

Major players of the genitourinary drugs market include Abbott Laboratories, Bayer AG, Eli Lilly& Co., Bristol-Myers Squibb Co., Astellas Pharma US, Inc., AstraZeneca PLC, GlaxoSmithKline PLC, Merck & Co., Inc., Pfizer,Inc., Johnson & JohnsonService, Inc,Hoffman-La Roche AG, and Melinta Therapeutics Inc.

The Report Covers

• Market value data analysis of 2018 and forecast to 2025.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global genitourinary drugs market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.